Gene: GATA5

140628
CHTD5|GATAS|bB379O24.1
GATA binding protein 5
protein-coding
20q13.33
Ensembl:ENSG00000130700 MIM:611496 Vega:OTTHUMG00000032919 UniprotKB:Q9BWX5
NG_046963.1
PubMed|SNP Mapped
1   ANCO-SNPs
ND|AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
6.026e-1 (AD)  5.486e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs6061245chr20:62469171 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TAS2R600.603
MUC170.59
IL200.553
ITK0.549
SLC2A90.541
DMRTB10.537
CALCA0.529
TEX190.521
LRRC150.52
OTOR0.511

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CASC1-0.256
GTDC1-0.243
GPR150-0.236
VSTM5-0.235
MEPE-0.233
SLC6A5-0.233
CKMT1B-0.232
C2orf27A-0.23
PLCXD3-0.23
IPCEF1-0.228

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA5 mRNA"27188386
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of GATA5 mRNA24449571
D001151ArsenicArsenic affects the methylation of GATA5 gene25304211
D001645BiguanidesBiguanides analog affects the expression of GATA5 mRNA17463086
C006780bisphenol Abisphenol A affects the expression of GATA5 mRNA21786754
C006780bisphenol Abisphenol A results in decreased expression of GATA5 mRNA25181051
C018475butyraldehydebutyraldehyde results in increased expression of GATA5 mRNA26079696
C584509C646 compoundC646 compound results in increased expression of GATA5 mRNA26191083
D002737ChloropreneChloroprene results in decreased expression of GATA5 mRNA23125180
C074702chromium hexavalent ionchromium hexavalent ion affects the expression of GATA5 mRNA28472532
D003561CytarabineCytarabine results in decreased expression of GATA5 mRNA21198554
C014347decitabinedecitabine affects the expression of GATA5 mRNA23300844
D003976DiazinonDiazinon results in increased methylation of GATA5 gene22964155
D002945CisplatinCisplatin affects the expression of GATA5 mRNA23300844
D004397FonofosFonofos results in increased methylation of GATA5 promoter22847954
D006861Hydrogen PeroxideGATA5 protein promotes the reaction [Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2L1 mRNA]]25726415
D006861Hydrogen PeroxideHydrogen Peroxide results in decreased expression of GATA5 mRNA25726415
D006861Hydrogen PeroxideHydrogen Peroxide results in decreased expression of GATA5 protein25726415
D006861Hydrogen PeroxideNitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of GATA5 mRNA]25726415
D006861Hydrogen PeroxideNitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of GATA5 protein]25726415
C082359imidaclopridimidacloprid results in decreased expression of GATA5 protein27792329
D008713MethimazoleMethimazole results in increased expression of GATA5 mRNA22504374
D008727MethotrexateMethotrexate affects the expression of GATA5 mRNA18502557
D009569Nitric OxideGATA5 protein promotes the reaction [Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2L1 mRNA]]25726415
D009569Nitric OxideGATA5 protein promotes the reaction [Nitric Oxide results in increased expression of BCL2L1 mRNA]25726415
D009569Nitric OxideGATA5 protein results in increased susceptibility to Nitric Oxide25726415
D009569Nitric OxideNitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of GATA5 mRNA]25726415
D009569Nitric OxideNitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of GATA5 protein]25726415
D009569Nitric OxideNitric Oxide results in increased expression of GATA5 mRNA25726415
D009569Nitric OxideNitric Oxide results in increased expression of GATA5 protein25726415
D010278ParathionParathion results in increased methylation of GATA5 promoter22847954
C006253pirinixic acidpirinixic acid results in decreased expression of GATA5 mRNA17426115
D010936Plant ExtractsPlant Extracts results in decreased expression of GATA5 mRNA23557933
D011073PolyaminesPolyamines analog affects the expression of GATA5 mRNA17463086
D011073PolyaminesPolyamines analog results in increased expression of GATA5 mRNA19934284
C005556propionaldehydepropionaldehyde results in increased expression of GATA5 mRNA26079696
D011441PropylthiouracilPropylthiouracil results in increased expression of GATA5 mRNA22504374
D012293Rifampin[Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA21127053
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of GATA5 mRNA25895662
C016104sodium bichromatesodium bichromate results in decreased expression of GATA5 mRNA24612858
C012568terbufosterbufos results in increased methylation of GATA5 promoter22847954
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of GATA5 mRNA21570461|2405805
D014118Toxins, Biological"Toxins, Biological affects the expression of GATA5 mRNA"19682533
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA5 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of GATA5 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of GATA5 mRNA24383497|2627250
D014635Valproic AcidValproic Acid results in increased methylation of GATA5 gene29154799
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of GATA5 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000978RNA polymerase II proximal promoter sequence-specific DNA binding-IBA21873635  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0000982transcription factor activity, RNA polymerase II proximal promoter sequence-specific DNA binding-ISS-  
GO:0001076transcription factor activity, RNA polymerase II transcription factor binding-IBA21873635  
GO:0001077transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding-IBA21873635  
GO:0001158enhancer sequence-specific DNA binding-IEA-  
GO:0003700DNA-binding transcription factor activity-IBA21873635  
GO:0003700DNA-binding transcription factor activity-IDA14986113  
GO:0003705transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding-IEA-  
GO:0008270zinc ion binding-IEA-  
GO:0044212transcription regulatory region DNA binding-IDA9566909  
GO ID GO Term Qualifier Evidence PubMed
GO:0003180aortic valve morphogenesis-IMP22641149  24638895  
GO:0003180aortic valve morphogenesis-ISS-  
GO:0003274endocardial cushion fusion-ISS-  
GO:0006366transcription by RNA polymerase II-IEA-  
GO:0007507heart development-IBA21873635  
GO:0007596blood coagulation-TAS-  
GO:0009887animal organ morphogenesis-IBA21873635  
GO:0009888tissue development-IBA21873635  
GO:0010614negative regulation of cardiac muscle hypertrophy-IEA-  
GO:0010628positive regulation of gene expression-ISS-  
GO:0010629negative regulation of gene expression-ISS-  
GO:0035481positive regulation of Notch signaling pathway involved in heart induction-ISS-  
GO:0045165cell fate commitment-IBA21873635  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA14986113  
GO:0048468cell development-IBA21873635  
GO:0048565digestive tract development-IBA21873635  
GO:0048646anatomical structure formation involved in morphogenesis-IBA21873635  
GO:0060575intestinal epithelial cell differentiation-IDA9566909  
GO:0062000positive regulation of cardiac endothelial to mesenchymal transition-ISS-  
GO:0071773cellular response to BMP stimulus-IEA-  
GO:1901228positive regulation of transcription from RNA polymerase II promoter involved in heart development-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000790nuclear chromatin-ISS-  
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-IDA9566909  
GO:0005654nucleoplasm-TAS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-109582HemostasisTAS
R-HSA-983231Factors involved in megakaryocyte development and platelet productionTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
22199344Clinical significance of hypermethylation status in NSCLC: evaluation of a 30-gene panel in patients with advanced disease. (2011 Dec)Pesek MAnticancer Res